Attovia Therapeutics (ATTO) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Gyre Therapeutics is the larger company by market cap ($746.5 million vs $740.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | GYRE |
|---|---|---|
| Share price | $16.21 | $7.04 |
| Market cap | $740.01M | $746.48M |
| 1-day change | -0.61% | +4.14% |
| YTD return | — | -0.28% |
| 1-year return | — | -1.54% |
| 5-year return | — | -88.27% |
| Forward P/E | — | 117.33 |
| EPS (TTM) | $-2.74 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $9.42 |
| 52-week low | $15.48 | $5.44 |
| Distance from 52-week high | -42.11% | -25.27% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +160.33% | +165.20% |
| Average volume | 457.37K | 105.93K |
| Shares outstanding | 45.65M | 106.03M |
| Employees | 44 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
ATTO vs GYRE FAQ
Which is bigger, Attovia Therapeutics or Gyre Therapeutics?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $746.48M compared with $740.01M for Attovia Therapeutics (ATTO).
Are Attovia Therapeutics and Gyre Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Attovia Therapeutics and Biotechnology: Pharmaceutical Preparations for Gyre Therapeutics.